These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2647864)

  • 1. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy.
    Clemens JD; Sack DA; Harris JR; Chakraborty J; Khan MR; Huda S; Ahmed F; Gomes J; Rao MR; Svennerholm AM
    J Infect Dis; 1989 Apr; 159(4):770-3. PubMed ID: 2647864
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
    Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
    Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
    Anh DD; Canh DG; Lopez AL; Thiem VD; Long PT; Son NH; Deen J; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Holmgren J; Clemens J
    Vaccine; 2007 Jan; 25(6):1149-55. PubMed ID: 17055622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholera vaccine inactivated oral.
    Drugs R D; 1999 Sep; 2(3):193-4. PubMed ID: 10641223
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
    Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD
    Lancet; 2009 Nov; 374(9702):1694-702. PubMed ID: 19819004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.
    Qadri F; Wierzba TF; Ali M; Chowdhury F; Khan AI; Saha A; Khan IA; Asaduzzaman M; Akter A; Khan A; Begum YA; Bhuiyan TR; Khanam F; Chowdhury MI; Islam T; Chowdhury AI; Rahman A; Siddique SA; You YA; Kim DR; Siddik AU; Saha NC; Kabir A; Cravioto A; Desai SN; Singh AP; Clemens JD
    N Engl J Med; 2016 May; 374(18):1723-32. PubMed ID: 27144848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission.
    Ali M; Emch M; Yunus M; Sack D; Lopez AL; Holmgren J; Clemens J
    Pediatr Infect Dis J; 2008 Jan; 27(1):33-7. PubMed ID: 18162935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" Vaccine 2007;25(8):1353-4.
    Thiem VD; Canh DG; Anh DD; Deen JL; von Seidlein L; Clemens JD; Holmgren J
    Vaccine; 2007 Nov; 25(47):7981-3. PubMed ID: 17933443
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children.
    Saha A; Chowdhury MI; Nazim M; Alam MM; Ahmed T; Hossain MB; Hore SK; Sultana GN; Svennerholm AM; Qadri F
    Vaccine; 2013 Jan; 31(4):647-52. PubMed ID: 23200936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
    Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
    Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.
    Qadri F; Ali M; Lynch J; Chowdhury F; Khan AI; Wierzba TF; Excler JL; Saha A; Islam MT; Begum YA; Bhuiyan TR; Khanam F; Chowdhury MI; Khan IA; Kabir A; Riaz BK; Akter A; Khan A; Asaduzzaman M; Kim DR; Siddik AU; Saha NC; Cravioto A; Singh AP; Clemens JD
    Lancet Infect Dis; 2018 Jun; 18(6):666-674. PubMed ID: 29550406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India.
    Ali M; Sur D; You YA; Kanungo S; Sah B; Manna B; Puri M; Wierzba TF; Donner A; Nair GB; Bhattacharya SK; Dhingra MS; Deen JL; Lopez AL; Clemens J
    Clin Infect Dis; 2013 Apr; 56(8):1123-31. PubMed ID: 23362293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial.
    Fong Y; Halloran ME; Park JK; Marks F; Clemens JD; Chao DL
    BMC Infect Dis; 2018 Feb; 18(1):84. PubMed ID: 29463233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herd protection and herd amplification in cholera.
    Sack DA
    J Health Popul Nutr; 2006 Mar; 24(1):1-5. PubMed ID: 16796143
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccines for cholera control: does herd immunity play a role.
    von Seidlein L
    PLoS Med; 2007 Nov; 4(11):e331. PubMed ID: 18044982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholera vaccines.
    Tacket CO; Clemens J; Kaper JB
    Biotechnology; 1992; 20():53-68. PubMed ID: 1600389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India.
    Kanungo S; Desai SN; Saha J; Nandy RK; Sinha A; Kim DR; Bannerjee B; Manna B; Yang JS; Ali M; Sur D; Wierzba TF
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003809. PubMed ID: 26023778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.
    Ali M; Emch M; von Seidlein L; Yunus M; Sack DA; Rao M; Holmgren J; Clemens JD
    Lancet; 2005 Jul 2-8; 366(9479):44-9. PubMed ID: 15993232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.